Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer

Nabil Saba • 1 Jun 2026
ASCO 2026
Thyroid Cancer

Nabil Saba, MD, of Emory University, discusses the latest ASCO guidelines on the systemic treatment of thyroid cancer, highlighting treatment sequencing in radioiodine-refractory differentiated thyroid cancer and emerging systemic approaches for aggressive subtypes, including anaplastic thyroid cancer. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nabil Saba

NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
3:02
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
Nabil Saba • 1 Jun 2026
DNA immunotherapy (INO-3107) in HPV-6 & 11 recurrent respiratory papillomatosis: long-term efficacy
2:42
DNA immunotherapy (INO-3107) in HPV-6 & 11 recurrent respiratory papillomatosis: long-term efficacy
Nabil Saba • 20 Oct 2025

Related Videos

Innovations improving outcomes and quality of life in thyroid malignancies
4:00
Innovations improving outcomes and quality of life in thyroid malignancies
Xiangqian Zheng • 6 Nov 2025
Patient-derived organoids guide personalized therapy in thyroid cancer
1:31
Patient-derived organoids guide personalized therapy in thyroid cancer
Mauro Cives • 18 Oct 2025
The evolving treatment landscape for BRAFm anaplastic thyroid cancer
1:35
The evolving treatment landscape for BRAFm anaplastic thyroid cancer
Mark Zafereo • 31 May 2025
Shifts in the treatment landscape for BRAFm anaplastic thyroid cancer
1:34
Shifts in the treatment landscape for BRAFm anaplastic thyroid cancer
Mark Zafereo • 31 May 2025
The content of VJOncology is intended for healthcare professionals